All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The ALL Hub

Brought to you by Scientific Education Support

Scientific Education Support

The ALL Hub is an independent medical education platform, sponsored by Amgen and Autolus. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My ALL Hub

Create an account to access:

Bookmark & personalize site content

Receive alerts for new content in your areas of interest

View ALL content recommended for you

#ASCO22

Share:

Jun 3, 2022

X post image

30 Nov 2022

Here's what you might have missed:
🎥 #ASCO22 | The ALL Hub spoke with Bijal D. Shah, Moffit Cancer Center. We asked for a ZUMA-3 trial update of brexucabtagene autoleucel in adult patients with R/R B-ALL.#leusm #allsm
Watch here 👉 https://t.co/ZolyjAGcj2.

X post image

25 Jul 2022

🎥 During #ASCO22, the ALL Hub spoke with Bijal D. Shah, @MoffittNews. We asked for a ZUMA-3 trial update of brexucabtagene autoleucel in adult patients with R/R B-ALL.
#leusm #allsm
Watch here 👇
https://t.co/ZolyjAGcj2

X post image

9 Jun 2022

📢For all our live congress coverage from #ASCO22 check out our twitter moment!

📚If you want to see more, visit the ALL Hub for drug updates, articles and interviews with key opinion leaders!

⭐️ https://t.co/eAeE0378b4 ⭐️

#leusm #ALLsm #leukemia

https://t.co/ISNeWCLVLu

X post image

7 Jun 2022

We hope you enjoyed following our live updates and congress coverage! 🎓

#ASCO22 was covered by us in Chicago, IL, as well as virtually!

Keep an eye on our socials for post-congress key points and insights! 📲

#medicalcongress #cancerawareness

X post image

7 Jun 2022

CONGRESS #ASCO22 | Laura Hogan @StonyBrookMed reports on the DELPHINUS phase II study of dara +VLPD in pediatric (P) & YA pts with R/R T-ALL or lymphoblastic lymphoma. N=24. ORR was 83.3% in P-, 60.0% in YA-ALL & 50.0% in LL pts. 41.7% P-ALL pts achieved MRD negativity #leusm

X post image

7 Jun 2022

CONGRESS #ASCO22 | Luke Devon Maese @huntsmancancer presents phase II/III data on IM recomb Erwinia asparaginase (asp) in ALL or LBL (n=167) Results were positive with IM JZP458 dosing regimen of 25/25/50 mg/m2 MWF & a similar safety profile vs other asp #leusm #leukemia

X post image

7 Jun 2022

CONGRESS #ASCO22 | Etan Orgel @ChildrensLA discusses the impact of age, obesity & body surface area on asparaginase-toxicity during ALL induction therapy (N=4,925). Risk for tox was increased in patients >10 years with obesity & high BSA, but not high BSA alone #leusm #leukemia

X post image

7 Jun 2022

CONGRESS #ASCO22 | Alexander Starodub @ChristHospital discusses KT-333 a STAT-3 degrader in a phase Ia trial (n=40) in pts with R/R lymphomas looking for the RP2D. A phase Ib trial (n=80) will explore safety, PK, PD & clinical activity of KT-333 in pts with LGL #leukemias #leusm

X post image

7 Jun 2022

It’s the last day of @ASCO!
Don’t miss our final live updates!
Closing interviews, key insights & congress coverage 📲

Sessions covered 👇
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes & Allotransplant
Pediatric Oncology

#ASCO22 #medicalcongress #cancerawareness

X post image

6 Jun 2022

CONGRESS #ASCO22 | @LuskinMarlise @DanaFarber shares data on novel approaches to #ALL in older adults. She makes reference to changes in treatment patterns and highlights how participation in clinical trials is essential for continued improvements in this field.
#leusm #leukemia

X post image

6 Jun 2022

CONGRESS #ASCO22 | @LoriMuffly @Stanford talks through the role of ASCT and cellular therapies in adults with #ALL. She highlights the benefits and drawbacks of commercially available CAR T therapies and considers some future perspectives in the area.

#leukemia #leusm

X post image

6 Jun 2022

CONGRESS #ASCO22 | @ECurranMD discusses advances in management of #ALL in adolescents and young adults (AYAs).

While OS of AYAs with #ALL has improved, further work is needed to optimise treatment regimens, particularly with regards to psychosocial barriers.

#leusm #leukemia

X post image

5 Jun 2022

CONGRESS #ASCO22 | Jessica Leonard @OHSUNews discusses immunotherapy in ALL with reference to the previous 3 posters. She highlights the viability of using blina in the frontline setting. She also considers the current drawbacks with approved immunotherapies #leusm #leukemia

X post image

4 Jun 2022

CONGRESS #ASCO22 | @WNMacaron @MDAndersonNews delivers results from a phase II study of mini-hyper CVD + inotuzumab ozogamicin +/- blinatumomab in pts ≥60 years with ND Ph-ve B-ALL. N=80. 99% responded, 89% CR. 80% pts were MRD-ve after 1 cycle & 94% overall. #leusm #leukemia

X post image

4 Jun 2022

CONGRESS #ASCO22 | @bshah @MoffittNews talks through the longer follow-up results of the ZUMA-3 trial of KTE-X19 in patients with R/R B-ALL (N=55). Median follow-up of 26.8 months CR/CRi rate 71%. 11 went on to allo-SCT with a subsequent median DoR of 14.6 months #leusm #leukemia

X post image

4 Jun 2022

CONGRESS #ASCO22 | @NicholasShortMD @MDAndersonNews reports on a phase II study of ponatinib + blinatumomab in pts with either ND Ph+ALL, R/R Ph+ALL or CML. (N=55) 96% ND ALL pts achieved CR/Cri and of the R/R Ph+ALL pts 92% achieved CR/CRi and 83% in CML pts #leusm #Leukemia

X post image

4 Jun 2022

CONGRESS #ASCO22 | Rohit Gupta @bcmhouston describes how loss of IKAROS increases JAK-STAT activity. Decreased expression of SOCS2 may allow increased JAK/STAT signaling in IKZF1 deleted cells #leusm #leukemia

X post image

4 Jun 2022

The ALL Hub will be covering the following session today virtually:

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Stay tuned for live updates, key insights, and interview coverage!

# ASCO22 #medicalcongress #cancerawareness

X post image

31 May 2022

The @ALL_Hub_ will be covering the 2022 ASCO Annual Meeting!

Date: 3–7 June
Location: Hybrid

Keep an eye on our socials for live coverage throughout the day from our virtual and in-person attendance in Chicago, IL! 🗣💻

#ASCO22 #medicalcongress #cancerawareness

X post image

23 May 2022

🧐Have you read these recommendations to improve participation rates of historically under-represented populations in cancer clinical trials

👉https://t.co/8E7WHACKrH👈

#lymsm #lymphoma #ASCO22

<span> </span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

ASCO 2022 American Society of Clinical Oncology

Newsletter

Subscribe to get the best content delivered to your inbox